로딩 중…
지수 로딩 중…
HLB PHARMACEUTICAL CO., LTD.
047920· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩8,240+7.99%
2026-08-04
Financials
Valuation Metrics
HLB PHARMACEUTICAL CO., LTD.'s Market Cap is ₩2703B. At end of 2025 it was ₩5261B. Ranked #678 of 2,436 in KR market (top 28%), #277 of 1,649 on KOSDAQ (top 17%), #77 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 270.27B KRW | KR#678/2,436 Sec#77/234 |
| Revenue | 236.59B KRW | KR#931/2,436 Sec#51/234 |
| Net Income | 3.72B KRW | KR#1,218/2,436 Sec#85/234 |
| Total Assets | 202.65B KRW | KR#1,269/2,436 Sec#95/234 |
| Net Assets | 151.73B KRW | KR#1,100/2,436 Sec#79/234 |
| Employees | 207 | KR#1,065/2,436 Sec#90/234 |
| Value | ||
| P/E | 72.58x | KR#1,403/2,436 Sec#92/234 |
| P/B | 1.78x | KR#1,899/2,436 Sec#139/234 |
| P/S | 1.14x | KR#1,487/2,436 Sec#86/234 |
| EV/EBITDA | 2557.96x | KR#1,566/2,436 Sec#111/234 |
| FCF Yield | -2.46% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 2.45% | KR#1,286/2,436 Sec#92/234 |
| ROA | 1.84% | KR#1,168/2,436 Sec#88/234 |
| Op. Margin | 0.05% | KR#1,591/2,436 Sec#112/234 |
| Revenue Growth | 89.49% | KR#164/2,436 Sec#21/234 |
| Earnings Growth | -54.09% | KR#1,224/2,436 Sec#78/234 |
| Financial Health | ||
| Debt Ratio | 133.56% | KR#916/2,436 Sec#108/234 |
| Total Debt | 15.00B KRW | KR#1,473/2,436 Sec#127/234 |
| FCF | -6.64B KRW | KR#1,579/2,436 Sec#126/234 |
| Cash | 4.34B KRW | KR#2,050/2,436 Sec#187/234 |
| Current Ratio | 1.90x | KR#1,010/2,436 Sec#114/234 |
| Net Debt/EBITDA | 97.05x | KR#1,562/2,436 Sec#111/234 |
| Performance | ||
| 1Y Return | -49.10% | KR#2,058/2,436 Sec#192/234 |
| 1M Return | -30.29% | KR#2,364/2,436 Sec#231/234 |
| From 52W High | -62.97% | KR#1,860/2,436 Sec#156/234 |
| 1Y MDD | -70.48% | KR#1,970/2,436 Sec#172/234 |
| Trading | ||
| Volume | 242,057 shares | KR#489/2,436 Sec#48/234 |
| Foreign Own. | 0.01% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 114 KRW | KR#1,335/2,436 Sec#94/234 |
| BPS | 4,626 KRW | KR#1,504/2,436 Sec#112/234 |
Company Info
동사는 1998년 씨트리로 설립되어 2020년 HLB그룹 편입과 함께 현 사명으로 변경함. 주요 사업은 전문의약품 제조·판매, 위수탁(CMO) 사업, 건강기능식품 판매이며, 로수듀오 등 160종 이상의 전문의약품을 위탁영업으로 판매하고 있음. 동탄 연구소 중심으로 주사제형 기반 신약 연구개발, 향남 신공장 신축으로 GMP 고도화, 시험 투자 확대로 경쟁력을 강화하고 있음. HLB제약는 1998년에 설립되었으며 경기도 남양주시에 본사를 두고 있습니다.